Hutchmed (China) Limited (HCM) has released an update.
HUTCHMED and Innovent Biologics announce that China’s NMPA has accepted their New Drug Application with priority review for a groundbreaking combination treatment of advanced endometrial cancer, featuring fruquintinib and sintilimab. This marks the first regulatory filing for the fruquintinib combination and targets a significant unmet need in China’s cancer treatment options, with supporting data to be presented at an upcoming medical conference.
For further insights into HCM stock, check out TipRanks’ Stock Analysis page.
